Pfizer PFE Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | $8.06B— | —— | $31.41B+42.6% | ||
| $6.59B-6.0% | $7.01B+11.5% | $6.29B+24.2% | $5.06B-2.4% | ||
| $799M-8.9% | $877M+67.0% | $525M-39.8% | $872M-26.2% | ||
| $12.29B-3.6% | $12.74B— | —— | $29.27B-10.2% | ||
| $2.63B-9.6% | $2.91B-25.5% | $3.91B+20.7% | $3.24B+19.4% | ||
| -$1.35B— | —— | -$33.17B-110% | -$15.78B+30.0% | ||
| -$10.9B+36.4% | -$17.14B— | —— | —— | ||
| —— | —— | —— | -$1.52B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pfizer generate?
- Pfizer (PFE) generated $12.6B in operating cash flow over the trailing twelve months.
- What is Pfizer's free cash flow?
- After $2.5B of capital expenditures, Pfizer's free cash flow was $12.5B over the trailing twelve months, up 26.6% year over year.
- Where does Pfizer's cash flow data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
